Last updated: February 13, 2026
Gadofosveset trisodium is an MRI contrast agent initially developed by Lantheus Medical Imaging. It was approved in the U.S. in 2011 for cardiovascular imaging but faced market challenges due to regulatory, competitive, and patent issues.
Market Dynamics
Regulatory Status and Usage
- Gadofosveset received FDA approval in 2011 for magnetic resonance angiography (MRA) targeting cardiovascular applications.
- It was marketed under the brand Vasovist in the U.S. and Ablavar internationally.
- The FDA withdrew approval in 2017, citing declining usage and commercial viability concerns, effectively halting U.S. sales.
- Some international markets continued to recognize regulatory approval post-2017, but uptake was limited.
Competitive Environment
- The contrast agent market is dominated by gadolinium-based compounds such as Gadovist, Magnevist, and Dotarem.
- These agents generally gained market share due to broader indications, established safety profiles, and cost advantages.
- Gadofosveset's unique albumin-binding property provided high relaxivity, but its benefits did not translate into significant market penetration.
Pricing and Reimbursement
- Pricing remained competitive for more established agents.
- Reimbursement policies favored agents with widespread approval and reimbursement codes.
- The lack of FDA approval since 2017 significantly affected reimbursement eligibility and market access in the U.S.
Market Size and Segments
- The global MRI contrast agent market was valued at approximately $2.2 billion in 2020, with projections reaching $3.2 billion by 2028.
- Gadofosveset's targeted segment—cardiovascular MRI—represented a smaller niche, estimated at around 10-15% of the overall contrast agent market.
- Its sales volume declined sharply after 2017, with limited potential for recovery given regulatory and competitive factors.
Financial Trajectory
Historical Sales Performance
- Prior to FDA withdrawal, Gadofosveset generated limited sales, estimated at under $50 million annually in the U.S.
- International sales contributed an additional $10-15 million per year, primarily through markets where licensing agreements persisted.
- Post-2017, U.S. sales ceased, and international revenue diminished due to licensing discontinuations and declining demand.
Current Valuation and Licensing
- Lantheus retains rights for the product outside the U.S., licensing it in select markets.
- Revenue from licensing deals remains small, with minimal growth prospects without regulatory reapproval.
- No significant pipeline updates or indications are publicly available that suggest future repositioning.
Development and Repositioning Potential
- The development of new indications or reformulation would require significant investment.
- Regulatory hurdles and market dominance by established contrast agents create substantial barriers to renewed commercialization.
Outlook and Strategic Considerations
- Gadofosveset's market presence is effectively defunct within the U.S., with minimal international activity.
- The market has shifted toward newer agents with better safety profiles, broader indications, and favorable reimbursement.
- Any attempt to reposition the molecule for specific niche indications would require substantial clinical trials and regulatory approval.
Key Takeaways
- Gadofosveset trisodium is no longer marketed or approved in the U.S. since 2017.
- International licensing yields limited revenue, constrained by market dominance of established contrast agents.
- The global MRI contrast agent market continues to grow, but gadofosveset’s niche is unlikely to recover without regulatory reapproval.
- The competitive environment favors newer agents, reducing the viability for repositioning.
- Current sales and valuation are negligible; future financial value depends on strategic licensing and development efforts.
FAQs
1. Can Gadofosveset trisodium be reapproved by the FDA?
Reapproval is technically possible but unlikely without significant clinical data demonstrating safety and efficacy improvements or new indications. The FDA's withdrawal was driven by declining sales and safety concerns.
2. What are the main competitors to Gadofosveset?
Gadovist, Magnevist, and Dotarem serve as primary competitors—widely used gadolinium contrast agents with extensive approval and established safety profiles.
3. How does the market size impact the potential for Gadofosveset?
Its targeted segment accounts for a small portion of the MRI contrast agent market, limiting revenue opportunities even if reapproved.
4. Is there any current licensing or commercial activity for Gadofosveset outside the U.S.?
Licensing exists, but activity is limited and sales are minimal. No recent data suggests active international commercialization.
5. What are the growth prospects for the overall MRI contrast agent market?
The market is expected to grow at a CAGR of approximately 4-5% through 2028, driven by increased imaging demand, but gadofosveset remains a minor player.
Sources:
[1] Market data from IBISWorld and MarketsandMarkets reports (2020-2022).
[2] FDA official notices and drug approval history.
[3] Lantheus financial disclosures and licensing agreements.
